Please use this identifier to cite or link to this item:
https://accedacris.ulpgc.es/handle/10553/73252
| Title: | KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? | Authors: | Rodríguez Abreu, D. Garassino, M. C. Esteban, E. Speranza, G. Felip, E. Domine, M. Hochmair, M. J. Powell, S. Cheng, S. Y-S. Bischoff, H. G. Peled, N. Hui, R. Reck, M. Garon, E. B. Boyer, M. Grossi, F. Jennens, R. Yang, J. Pietanza, M. C. Gadgeel, S. |
UNESCO Clasification: | 320101 Oncología | Issue Date: | 2018 | Journal: | Annals of Oncology | Conference: | European-Society-for-Medical-Oncology Asia Congress | URI: | https://accedacris.ulpgc.es/handle/10553/73252 | ISSN: | 0923-7534 | Source: | Annals of Oncology [ISSN 0923-7534], v. 29 (sup. 9), p. 164, Abstract 532P, (Noviembre 2018) |
| Appears in Collections: | Actas de congresos |
Adobe PDF (62,49 kB)
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.